Web Exclusives

Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia.

Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact.

Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features.

By keeping themselves physically and emotionally healthy, caregivers can give their loved ones the best possible support when helping to care for them.

June is Pride Month, and the LGBTQ patient population with cancer faces a disproportionate burden because of a lack of data, a misunderstanding of this population by providers, and a lack of resources and education for patients.

We have all been affected by the coronavirus pandemic in some way. For cancer survivors, it can be difficult to process the time lost to COVID-19 after surviving the hardships of cancer treatment.

The COVID-19 pandemic has resulted in several changes in how patients with chronic lymphocytic leukemia (CLL) are treated.

Better identification of patients at high risk of disease progression and newer treatments may mean that fewer newly diagnosed patients must “watch and wait.”

The use of telemedicine has shown rapid growth over the course of the pandemic, with some experts suggesting that it is here to stay.